Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-24C5 in Advanced Solid Tumors
NCT06187402Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-24C5 in solid tumor (advanced stage) (2 arms), sponsored by LaNova Medicines. Primary endpoints: Incidence of adverse events at 60 weeks, Incidence of dose-limiting toxicity at 60 weeks and 7 more. Started Dec 2023; status: recruiting.
02
Drugs
LM-24C5
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06187402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187402.